|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.00/-0.80
|
企業價值
3.49B
|
資產負債 |
每股賬面淨值
1.59
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
0.01
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/23 22:20 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |